MEDICENNA THERAPEUTICS CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.27 CAD | -4.22% |
|
-8.10% | +440.48% |
| May. 13 | Medicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program Committee | MT |
| May. 13 | Medicenna Brief: Providing Update on its Presentations at the 2024 ASCO Annual Meeting | MT |
Presentation Operator MessageOperator (Operator)Hello, and welcome to Medicenna Therapeutics f...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Companyâs IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Companyâs early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program is designed to enhance the ability of Superkines to treat immunologically cold tumors.
Calendar
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.37
CAD
Average target price
7
CAD
Spread / Average Target
+195.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +440.48% | 130M | |
| +33.63% | 50.85B | |
| -0.09% | 42.82B | |
| +49.62% | 42.03B | |
| -4.96% | 29.55B | |
| +11.18% | 26.11B | |
| -21.95% | 19.13B | |
| +8.61% | 13.05B | |
| +28.31% | 12.16B | |
| +24.73% | 12.08B |
- Stock Market
- Equities
- MDNA Stock
- News Medicenna Therapeutics Corp.
- Transcript : Medicenna Therapeutics Corp., Q1 2022 Earnings Call, Aug 13, 2021
